Street talk about Big Pharma bidders for Onyx Pharmaceuticals puts Pfizer and Bristol-Myers Squibb in the hunt, with biotech giant Amgen still leading the charge.
The field of potential Onyx bidders is beginning to narrow to a handful of likely candidates. By Reuters ' account, Amgen is still in hot pursuit, with Pfizer, Bristol-Myers Squibb and Gilead prowling the sidelines. Novartis, Sanofi, GlaxoSmithKline and Biogen Idec have bowed out, according to the same sources.
To keep its growing workforce trained, Roche is building a $105 million training center at a key plant in the Swiss company's home country, expected to open in October 2014.
These days, drugmakers almost always offer discounts to get their products cleared by NICE. But even that's not a sure bet for winning approval. Such was the case with Pfizer's Bosulif, rejected today for the treatment of chronic myeloid leukemia (CML).
China has fast become a huge pillar on the global R&D scene, with local CROs like WuXi PharmaTech and ShangPharma cashing in on demand for clinical trials in the country. But, with the FDA chiding a sloppy Chinese trial run by Bristol-Myers Squibb, Pfizer and PPD, regulators and researchers may think twice before accepting data gathered in the country.
The FDA will consider Eliquis for a new indication, one which Pfizer and partner Bristol-Myers Squibb hope can help the blood thinner hit the sales potential analysts predicted for the drug before it was approved.
It has been a mixed bag of news for Pfizer employees in Ireland in recent months, with the drug giant cutting jobs but then recommitting to production in the country. Pfizer pulled out some more good news today, saying it would invest $130 million in two plants there.
Prevnar pneumonia jabs have been wildly successful for Pfizer, racking up billions of dollars in sales and almost single-handedly driving its vaccine business.
One of the hottest competitions in drug development has spurred Amgen, Sanofi and Pfizer to invest heavily in PCSK9 drug programs aimed at lowering bad cholesterol in a way that could prove a game-changer in the field of heart disease.
One reason Pfizer snapped up Wyeth in 2009: Its Prevnar/Prevenar vaccine franchise. Now, the latest version of the pneumococcal shot is Pfizer's fourth-biggest seller, with $3.72 billion in 2012 revenues. But Pfizer wants even more.